Clever camouflage Zhejiang University team successfully developed “universal panda blood”

A person’s blood type is usually determined by antigens made up of certain inheritable glycoproteins and sugar chains on the surface of red blood cells. So far, more than 30 blood types like this have been found. For example, we are most familiar with the ABO blood type system composed of A, AB, B, O. The Rh blood type system is the most complex category in the classified red blood cell blood type system. In rh systems, if the surface of red blood cells contains D antigens, it is called RhD positive, and vice versa, it is called negative.

Existing scientific studies have found that RhD negative is very rare, for example in Asia, less than 0.5% of people are RhD-negative, so it is known as “panda blood”. The number of such populations is small and is often in short supply in clinical blood transfusions.

Zhejiang University Public issued a statement that the university’s department of chemistry, Professor Tang Ruikang, and the medical school affiliated with the second hospital / translational medicine institute Associate Professor Wang Ben joint research team successfully developed a “universal panda blood.” The study was published March 21 in the internationally renowned journal Science Advances.

It is mentioned that Tang Ruikang, Wang Ben team thought of using “easy-to-capacity” to “transform” RhD-positive red blood cells into RhD-negative. That is, by recreating a layer of cell membrane surface structure, the tentacles of the D antigen hidden. With such a layer of “disguise”, the antibody will not recognize antigens, will not cause an immune response.

It is understood that the study has been carried out for nearly 5 years. At present, “universal panda blood” has been in mice to achieve a safe single and multiple blood transfusion, with normal in vivo circulation time, but also in the rabbit body to verify the full masking of RhD antigen, and does not have immunogenicity.

Wang Ben revealed that the next step in addition to continuing to promote the “universal red blood cell” research work, clinical platelet infusion also to consider the matching type, the problem is more trouble than red blood cell matching, the relevant extension of research is being planned. “